CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques

AIDS

Volumn 18, Issue 7, 2004, Pages 1003-1008

  Verthelyi, Daniela ^a   Wang, Vivian W ^a   Lifson, Jeffrey D ^a   Klinman, Dennis M ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

CpG oligodeoxynucleotides; Hepatitis B vaccine; Rhesus macaques; SIV

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; OLIGODEOXYNUCLEOTIDE DERIVATIVE; RECOMBINANT HEPATITIS B VACCINE; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; VACCINATION; VIRUS INFECTION; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; MACACA MULATTA; OLIGODEOXYRIBONUCLEOTIDES; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 2342470820     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200404300-00007     Document Type: Article

References (33)

1. Rustgi VK, Hoofnagle JH, Gerin JL, Gelmann EP, Reichert CM, Cooper JN, et al. Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med 1984, 101:795-797.
2. Cooley L, Sasadeusz J. Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1. J Clin Virol 2003, 26:185-193.
3. Homann C, Krogsgaard K, Pedersen C, Andersson P, Nielsen JO. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr 1991, 4:416-420.
4. Puoti M, Airoldi R, Zanini A, Spinetti A, Pezzoli C, Patroni A, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002, 4:27-35.
5. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997, 336:196-204.
6. Horowitz MM, Ershler WB, McKinney WP, Battiola RJ. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med 1988, 108:185-189.
7. Choudhury SA. Responses to hepatitis B vaccine boosters in human immunodeficiency virus infected children. Pediatr Infect Dis J 1995, 14:65-67.
8. Dianmant EP, Schlechter C, Hodes DS, Peters VB. Immunogenicity of hepatitis B vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1993, 12:877-878.
9. Wong EKL, Bodsworth NJ, Slade MA, Mulhall BP, Donovan B. Response to hepatitis b vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 1996, 7:490-494.
10. Hemmi H, Takeuchi O, Kawai T, Sato S, Sanjo H, Matsumoto M, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
11. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001, 194:863-869.
12. Takeshita F, Leifer CA, Cursel I, Ishii K, Takeshita S, Gursel M, et al. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001, 167:3555-3558.
13. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
14. Klinman DM, Takeshita F, Gursel I, Leifer C, Ishii KJ, Verthelyi D, et al. CpG DNA: recognition by and activation of monocytes. Microb Infect 2002, 4:897-901.
15. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol 2001, 166:2372-2377.
16. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. CpG oligodeoxynudeotides as vaccine adjuvants in primates. J Immunol 2002, 168:1659-1663.
17. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, et al. Delineation of a CpG phosphorothioate oligodeoxinucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000, 164:1617-1624.
18. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, et al. Identification of CpG oligonudeotide sequences with high induction of IFNa/b in plasmacytoid dendritic cells. Eur J Immunol 2001, 31:2154-2163.
19. Gursel M, Verthelyi D, Klinman DM. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol 2002, 32:2617-2622.
20. Jones TR, Obaldia N, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys. Vaccine 1999, 17:3065-3071.
21. Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamzah SS, et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000, 19:413-422.
22. Leifer CA, Verthelyi D, Klinman DM. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J Immunother 2003, 26:313-319.
23. Lifson JD, Rossio JL, Piatak M, Jr, Parks T, Li L, Kiser R, et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 2001, 75:10187-10199.
24. Azzoni L, Papasavvas E, Chehimi J, Kostman JR, Mounzer K, Ondercin J, et al. Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J Immunol 2002, 168:5764-5770.
25. Chehimi J, Starr SE, Frank I, D'Andrea A, Ma X, MacGregor RR, et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994, 179:1361-1366.
26. Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002, 168:4796-4801.
27. Feldman S, Stein D, Amrute S, Denny T, Garcia Z, Kloser P, et al. Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol 2001, 101:201-210.
28. Verthelyi D, Zeuner RA. Differential signaling by CpG DNA in DCs and 8 cells: not just TLR9. Trends Immunol 2003, 24:519-522.
29. Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000, 18:1161-1165.
30. Newell A, Francis N, Nelson M. Hepatitis and HIV: interrelationship and interactions. Br J Clin Pract 2003, 49:247-251.
31. Verthelyi D, Gursel M., Kenney RT, Lifson JD, Shuying L, Mican J, et al. CpG oligodeoxynucleotides protect normal and SIV infected macaques from Leishmania infection. J Immunol 2003, 170:4717-4723.
32. Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001, 98:3016-3021.
33. Donaghy H, Pozniak A, Gazzard B, Qazi N, Gilmour J, Gotch F, et al. Loss of Mood CD11c+ myeloid and CD11c{-} plasmacytoid dendritic eels in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 2001, 98:2574-2576.